case_images: PMC9035953_01
case_images: Basal choline PET/TC at the beginning of MA treatment reveals progressing mediastinal nodal metastases.
case_images: cro-0015-0312-g01.jpg
case_images: PMC9035953_01_cro-0015-0312-g01.jpg
case_images: F1
case_images: PET/TC revealed the appearance of new bone metastases in right humerus, sternum, left acetabulum, and eighth dorsal vertebra and progressive disease in left hemicostat and mediastinal lymph nodes metastases (shown in Fig. 1, 2). PSA raised to 65.72 ng/mL and patient reported severe pain in his right arm and left hip.
case_images: Basal choline PET/TC at the beginning of MA treatment reveals appearance of new bone metastases.
case_images: cro-0015-0312-g02.jpg
case_images: PMC9035953_01_cro-0015-0312-g02.jpg
case_images: F2
case_images: PET/TC revealed the appearance of new bone metastases in right humerus, sternum, left acetabulum, and eighth dorsal vertebra and progressive disease in left hemicostat and mediastinal lymph nodes metastases (shown in Fig. 1, 2). PSA raised to 65.72 ng/mL and patient reported severe pain in his right arm and left hip.
case_images: Choline PET/TC after 9 months of MA treatment (January 2020) reveals an important uptake reduction in bone metastases and a metabolic CR in mediastinal nodal metastases.
case_images: cro-0015-0312-g03.jpg
case_images: PMC9035953_01_cro-0015-0312-g03.jpg
case_images: F3
case_images: In January 2020, choline PET/TC revealed an important uptake reduction in bone metastases (shown in Fig. 3).